Flux Power Holdings Inc vs Repligen Corporation Common Stock — how do they compare? Flux Power Holdings Inc trades at $0.43 (market cap $10.06M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 1107.4× Flux Power Holdings Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 21 Days and Repligen Corporation Common Stock for 0 Days on average.
| FLUX | RGEN | |
|---|---|---|
Market Cap | $10.06M | $11.14B |
Volume | 188,430 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $6.66 | $194.57 |
52-Week Low | $0.41 | $102.87 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $18.26M | $11.02B |
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4652, down 0.04% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported revenue of $66.43 million in 2025 but posted a net loss of $6.67 million, with profitability metrics showing negative ROE and ROA. Recent news highlights acquisition interest from Solidion Technology, which Flux Power's board rejected in October 2026, creating uncertainty around strategic direction.
The outlook remains challenged by persistent losses and declining revenue projections for 2026, though analyst consensus is unanimously bullish with 6 buy ratings. Key risks include execution on profitability, competitive pressures in energy storage, and potential acquisition volatility. The stock's valuation at 0.22 P/S offers potential if operational improvements materialize.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →